Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;24(8):643-654.
doi: 10.1007/s11883-022-01041-7. Epub 2022 May 28.

Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

Mohamad B Taha  1   2 , Tamer Yahya  1   2 , Priyanka Satish  1 , Rachel Laird  1 , Arthur S Agatston  3 , Miguel Cainzos-Achirica  1   2 , Kershaw V Patel  1 , Khurram Nasir  4   5
Affiliations
Review

Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

Mohamad B Taha et al. Curr Atheroscler Rep. 2022 Aug.

Abstract

Purpose of review: The burden of obesity worldwide is high and projected to rise. Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk factors; hence, utilizing effective long-term therapies for obesity is of utmost importance. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapies that achieve substantial weight loss and improve cardiometabolic risk. The purpose of this review is to discuss the role of GLP-1RAs in obesity management.

Recent findings: Two subcutaneous GLP-1RAs, liraglutide and semaglutide, have been evaluated in several clinical trials for weight loss. Liraglutide achieves a mean weight loss of 4-7 kg, and more than 50% of treated individuals achieve 5% or more weight loss. Semaglutide has a greater impact on weight loss, with a mean weight loss of 9-16 kg, and more than 50% of treated individuals achieve 10-15% or more weight loss. These results led to regulatory approval of these agents for weight loss in individuals with obesity, regardless of diabetes status. In addition to weight loss, the benefits of GLP-1RAs extend to other risk factors, such as glycemic control and blood pressure. Gastrointestinal symptoms are the most frequently encountered adverse events with incidences between 5 and 30%. Finally, the cost remains one of the most critical challenges that limit GLP-1RAs use. GLP-1RAs have robust weight loss benefits and are expected to have a critical role in the management of obesity in the coming years. Upcoming studies will evaluate the durability of weight loss achieved with GLP-1RAs and the impact on cardiovascular outcomes.

Keywords: Cardiovascular risk factors; Glucagon-like peptide 1 receptor agonists; Liraglutide; Obesity; Semaglutide; Weight loss.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW, Gortmaker SL. Projected U.S. State-level prevalence of adult obesity and severe obesity. New Englan J Med. 2019;381:2440–50.
    1. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002;347:59–60.
    1. Bogers RP, Bemelmans WJE, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, Van Dam RM, Hu FB, Visscher TLS, Menotti A, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167:1720–8. - PubMed
    1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–62. - PubMed - PMC
    1. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G, Selmer R, Strand BH, Dobson A, Hozawa A, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet. 2014;383:970–83. - PubMed

MeSH terms

Substances

LinkOut - more resources